Ceptur Therapeutics is a pre-clinical biotechnology company developing targeted oligonucleotide therapeutics using its proprietary U1 Adaptor technology. U1 Adaptors are bivalent oligonucleotides that engage sequence-specific mRNA and the U1 small nuclear ribonucleoprotein to control gene expression at the pre-mRNA level within the nucleus. The modality is positioned to address difficult targets by co-opting a ubiquitous regulator of transcription and splicing. Ceptur in-licensed and expanded its foundational U1 Adaptor IP portfolio in 2021 and has recruited a scientific advisory board of academic and industry leaders in oligonucleotide therapeutics. The company is headquartered in Hillsborough, New Jersey. It recently completed a $75M Series A financing to advance its broad discovery pipeline of differentiated genetic medicines.

Total raised

$75M

Funding rounds

1

Latest round

Series A

Latest activity

Jan 2022